

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 882 231 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
17.07.2002 Bulletin 2002/29

(51) Int Cl.7: G01N 33/53, C07D 305/00,
C07D 407/00, C07D 493/00,
C07D 305/14

(21) Application number: 97905879.9

(86) International application number:
PCT/US97/02069

(22) Date of filing: 13.02.1997

(87) International publication number:
WO 97/30352 (21.08.1997 Gazette 1997/36)

(54) RECOVERY OF TAXANES FROM CONIFERS

RÜCKGEWINNUNG VON TAXANEN AUS KONIFEREN
OBTENTION DE TAXANES A PARTIR DE CONIFERES

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC
NL PT SE

• VENTIMIGLIA, Frank, F.
Davis, CA 95616 (US)

(30) Priority: 14.02.1996 US 601367

(74) Representative: Goldin, Douglas Michael
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(43) Date of publication of application:
09.12.1998 Bulletin 1998/50

(73) Proprietor: The Regents of the University of
California
Oakland, CA 94607-5200 (US)

(56) References cited:
WO-A-96/02656 US-A- 5 019 504
US-A- 5 310 672

(72) Inventors:

• DURZAN, Don, J.
Davis, CA 95616 (US)

EP 0 882 231 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

BACKGROUND OF THE INVENTION

5 [0001] The present invention relates to the production and recovery of taxane compounds. In particular, it relates to methods of recovering taxanes from conifer plants other than members of the genus *Taxus*.

[0002] Taxane compounds, in particular paclitaxel (Taxol™), have significant antitumor activity and have been the focus of investigations to develop these compounds as drugs for the treatment of cancer. These compounds have also been shown to inhibit congenital polycystic kidney disease (Woo *et al. Nature* 368 759 (1994)). Paclitaxel, originally
10 isolated from the bark of the Pacific yew, *Taxus brevifolia*, was recently approved by the Food and Drug Administration for use against ovarian cancer and has also shown activity against breast, lung and other cancers.

[0003] Continued testing of paclitaxel and other taxanes require quantities which cannot be obtained from the scarce natural source. *T. brevifolia* is a rare tree, grows slowly, and is not cultivated. In addition, thousands of pounds of bark are required to produce one pound of paclitaxel. Moreover, extraction of the bark is complicated, and product variability
15 occurs.

[0004] Because of the scarcity of naturally occurring paclitaxel, numerous investigators have attempted to increase the supply of paclitaxel and other taxanes. For instance, cell suspension cultures of sporophytic tissues have been shown to produce paclitaxel (US Patent 5,019,504). In addition, recent reports describe the total synthesis of paclitaxel (see, Holton *et al. JACS* 116:1597 (1994) and Nicolaou *et al. Nature* 367:630 (1994)). These syntheses, however,
20 involve too many steps to be commercially feasible (Flann, *Science* 263:911 (1994)).

[0005] Increased availability of taxanes will facilitate investigations to synthesize analogs of paclitaxel or identify other taxanes with similar anti-tumor activity but having improved properties. For instance, paclitaxel is relatively insoluble in aqueous solutions. As a result, paclitaxel is usually dissolved in an oily base of castor oil and alcohol and administered in this form. The identification of related compounds with increased aqueous solubility could provide
25 compounds with better cellular penetration and efficacy than is found with paclitaxel.

[0006] Despite advances in the art, availability of paclitaxel and other taxane compounds remains a critical limitation in further investigation and therapeutic use of these compounds. The present invention addresses these and other needs.

30 SUMMARY OF THE INVENTION


[0007] The present invention provides methods of producing taxanes from members of the order Coniferales other than the genus *Taxus*. The methods comprise contacting the tissue with a composition which extracts taxanes. Any standard method for extracting taxanes may be used. Typically, an organic solvent, such as methanol is used. Any
35 part of the plant may be used as the tissue. Exemplary tissue included bark, cambium, stem, seed, cone, needle, or root tissue. Alternatively, a cell culture derived from the plant may be used. Exemplary genera which may be used in the methods include *Picea*, *Fitzroya*, *Cupressus*, and *Araucaria*.

[0008] In some embodiments, the methods include releasing bound taxanes, which are thought to be covalently bound to cell wall and other components and released by, for instance, hydrolysis of the cell wall components. Any
40 method of releasing bound taxanes can be used for this purpose. Typically, the bound taxanes are released by treating the tissue with a glycosidase, such as xylanase.

[0009] The invention also provides methods of screening plant tissue from conifer species for the presence of taxanes. The screening method comprise contacting plant tissue or an extract of the plant tissue with an antibody that is specifically reactive with a taxane and detecting the formation of an antigen-antibody complex. Useful antibodies for
45 this purpose include those in TA11, an anti-taxane, rabbit polyclonal serum. Alternatively, monoclonal antibodies such as 3C6, 8A10 and 3H5 can be used. If an extract of the tissue is used, a competitive inhibition enzyme linked immunoassay may be used to detect and quantitate taxane content.

Definitions

50 [0010] The terms "taxanes" refer to compounds comprising the tricyclic ring nucleus shown by



5
10 The chemical structure of taxanes and related compounds (e.g., Taxine A) is described in Gueritte-Vogelin *J. Nat. Prod.* 50:9-18 (1987).

[0011] Taxanes of the invention can also be identified through the use of monoclonal antibodies raised against paclitaxel and related compounds. A number of such antibodies are known and are commercially available. Suitable antibodies include 3C6, which is specifically reactive with paclitaxel and its C-7 derivatives, and 8A10 which cross reacts with paclitaxel, cephalomannine, baccatin III, and 10-deacetylbaccatin III (Kingston *et al.* *J. Nat. Prod.* 53:1-12 (1990)) and 3H5 which binds with equal affinity to baccatin III and its 7-epi isomer baccatin V. Cross-reactivity studies performed on these various antibodies by Hawaii Biotechnology indicate that the rabbit polyclonal serum recognizes epitopes restricted to the taxane C-13 side chain. Studies with the 3H5 monoclonal antibody indicate that epitope specificity for this antibody encompasses the C-10 through C-13 region of the molecule. The reactivity pattern for the 8A10 monoclonal antibody suggests a specificity for the C-6 through C-2 region. Further, monoclonal antibody 3C6 binds only those baccatin derivatives with a C-13 side-chain. Compounds used for these cross-reactivity studies include the following: Taxol, 10-Deacetyltaxol, 7-epi-10-Deacetyltaxol, 7-Xylosyl-10-deacetyltaxol, 7-epi-Taxol, Cephalomannine, Baccatin III, Baccatin V, 10-Deacetylbaccatin III, 7-epi-10-Deacetylbaccatin III, Taxotere (docetaxel), 2-debenzoyl-2-(p-trifluoromethylbenzoyl)taxol and 20-Acetoxy-4-deacetyl-5-epi-20,0-secotaxol. These antibodies are all commercially available from the Hawaii Biotechnology Group Inc., Alea, HI. Taxanes can be further identified by their chromatographic behavior in a "taxane" column and their characteristic UV spectra in the 190 to 600 nm range. Taxane-like activity can be assayed using an *in vitro* microtubule polymerization assay as described in U.S. Patent No. 5,019,504.

[0012] The term "bound taxanes" refers to taxane compounds produced by a plant cell that are not significantly extracted by standard solvent extraction methods, but are recovered after hydrolysis of plant materials. Without wishing to be constrained by any particular theory, such taxanes are thought to be covalently bound to cell wall and other components and released by, for instance, hydrolysis of the cell wall components. Hydrolysis is typically carried out by enzymatic cleavage. Other methods of releasing bound cell wall components can also be used.

[0013] As used herein the term "order Coniferales" is used in the standard taxonomic sense to refer to the taxonomic group of gymnosperms generally having well-defined cones. Members of this order are divided among seven plant families: Pinaceae (including e.g., *Pinus*, *Pseudotsuga*, *Abies*, *Picea*, and *Cedrus*), Taxodiaceae (including e.g., *Taxodium*, *Metasequoia*, and *Sequoia*), Cupressaceae (including e.g., *Cupressus*, *Juniperus*, *Thuja*, *Calocedrus*, and *Libocedrus*), Araucariaceae (including *Araucaria* and *Agathis*), Podocarpaceae (including e.g., *Podocarpus*, *Dacrydium*, and *Phyllocladus*), Cephalotaxaceae (*Cephalotaxus*), and Taxaceae (including *Taxus* and *Torreya*). See, e.g., Lawrence, *Taxonomy of Vascular Plants*, (Macmillan Company, 1951).

[0014] A "composition capable of extracting taxanes" is any composition, typically an organic solvent such as methanol, which can be used to extract taxanes and related compounds from plant tissues containing such compounds. A number of suitable compositions are known in the art. For instance, U.S. Patent No. 5,445,809 describes the isolation of taxanes using a "reactor compound" containing paclitaxel precursors. U.S. Patent No. 5,440,055 describes the use of "CoNC fluids" as solvents. As defined in that patent CoNC fluids are comprised of materials which exist as gases at ambient conditions, such as the gases carbon dioxide and nitrous oxide. When such gases are compressed and brought to conditions near or above their critical pressures and temperatures, such gases exhibit enhanced solvating power.

[0015] The phrase "specifically reactive with", when referring to the interaction between an antibody and an antigen, such as a taxane ring, refers to a binding reaction between the antigen and the antibody which is determinative of the presence of the antigen in the presence of a heterogeneous population of other compounds. Thus, under designated immunoassay conditions, the specified antibodies bind to a particular antigen against which they were developed and do not bind in a significant amount to other compounds present in the sample.

55 DESCRIPTION OF THE PREFERRED EMBODIMENT

[0016] The present invention provides new sources of taxanes from plants other than members of the genus *Taxus*. It has been found that a number of genera in the order Coniferales produce significant amounts of taxanes and are

therefore good sources of taxanes.

[0017] Standard methods for the isolation of taxanes and related compounds from *Taxus* tissues can be used. The particular method used to extract taxanes and related compounds is not critical to the invention. Typically, taxanes are extracted with organic solvents from the particular plant tissue and chromatographically purified. Adsorbent beads may be used to remove the taxanes produced. In addition, particulate matter released by the cells may be used to adsorb the taxanes. The particular adsorbent material is not a critical aspect of the invention, so long as the material provides a sink for removing the end-product from the reaction sequence.

[0018] The extraction process typically begins by contacting the tissue to be extracted with an alcohol (e.g., methanol) at elevated temperature, 50° to 55°C. The extract is then concentrated in methanol. Next, the concentrated methanol extract is partitioned between methylene chloride and water. The methylene chloride fraction, containing paclitaxel, is concentrated. The methylene chloride concentrate is dissolved in 50/50 acetone:hexane, and the mixture is filtered to remove insolubles.

[0019] The taxanes are then purified from the acetone:hexane mixture using a variety of chromatographic methods. For instance, the purification of paclitaxel is typically carried out using chromatography on Florisil columns in a 70/30 hexane:acetone mixture to separate the paclitaxel containing fractions. The paclitaxel fractions are then concentrated to dryness. Paclitaxel concentrates are crystallized from a methanol:water mixture and then recrystallized from an acetone:hexane mixture yielding 85 to 95% pure paclitaxel. The paclitaxel is then chromatographed on silica gel with either 2.5% isopropanol or 2.5% n-butanol in methylene chloride to yield approximately 98% pure paclitaxel.

[0020] The present invention also provides methods of screening plant tissues for the presence of taxanes and related compounds. Such methods typically involve a competitive inhibition enzyme immunoassay (CIEIA) using an anti-taxane antibody as described above. 8A10 is particularly useful for this purpose because it is specific for a common epitope of the tetracyclic taxane nucleus and is known to be capable of detecting the compounds listed in Table 1.

Table 1

	Taxane	IC ₅₀ nanomolar
1.	paclitaxel	7
2.	10-deacetyltaxol	10
3.	7-epi-10-deacetyltaxol	15
4.	7-xylosyl-10-deacetyltaxol	17
5.	cephalomannine	8
6.	baccatin III	12
7.	baccatin V	10
8.	10-deacetylbaccatin III	21
9.	7-epi-10-deacetylbaccatin III	27
Note: IC ₅₀ = The concentration of analyte required for 50% inhibition of binding of the antibody to the solid phase antigen in CIEIA.		

[0021] In some embodiments, tissue cultures derived from the plant tissue of interest are established. Methods for establishing and maintaining plant tissue cultures are well known in the art (see, e.g., P.R. White, 1954, *Cultivation of Animal and Plant Cells* Ronald Press, New York). Typically, the plant material is surface-sterilized prior to introducing it to the culture medium. Any conventional sterilization technique, such as chlorinated bleach treatment can be used. In addition, antimicrobial agents may be included in the growth medium. Under appropriate conditions plant tissue cells form callus tissue, which may be grown either as solid tissue on solidified medium or as a cell suspension cells in a liquid medium. Metabolic products of the callus, such as taxol or other alkaloids, may be isolated from the callus cells or from the culture medium using known techniques (see, e.g., U.S. Patent No. 5,019,504).

[0022] A number of suitable culture media for callus induction and subsequent growth on aqueous or solidified media are known. Exemplary media include standard growth media, many of which are commercially available (e.g., Sigma Chemical Co., St. Louis, MO). Examples include Schenk-Hildebrandt (SH) medium, Linsmaier-Skoog (LS) medium, Murashige and Skoog (MS) medium, Gamborg's B5 medium, Nitsch & Nitsch medium, White's medium, and other variations and supplements well known to those of skill in the art (see, e.g., *Plant Cell Culture*, Dixon, ed. IRL Press, Ltd. Oxford (1985) and George *et al.*, *Plant Culture Media*, Vol 1, Formulations and Uses Exegetics Ltd. Wilts, UK, (1987)). For the growth of conifer cells, particularly suitable media include 1/2 MS, 1/2 L.P., DCR, Woody Plant Medium (WPM), Gamborg's B5 and its modifications, DV (Durzan and Ventimiglia, *In Vitro Cell Dev. Biol.* 30:219-227 (1984)), SH, and White's medium.

[0023] Taxanes, referred to here as "bound taxanes" can also be located on the surfaces of various plant cells and tissues. Enzyme treatment of exhaustively extracted tissues yields taxanes that are detectable by HPLC. By contrast,

Table 2 (continued)

<i>Araucaria excelsa</i>	Whole branch + needles
<i>Araucaria angustifolia</i>	Tissue culture material
<i>Fitzroya cupressoides</i>	Branch + needles
<i>Picea abies</i>	Tissue culture material grown on 1/2 LP medium*
<i>Picea abies</i>	Tissue culture material grown on 1/2 LP medium supplemented with 100 mg/liter colchicine (col).
<i>Cupressus sempervirens</i>	Tissue culture material
<i>Araucaria angustifolia</i>	Bark from a dead tree

*Von Arnold J. Plant Physiol. 127:233-244 (1987).

[0035] CIEIA was performed blind using the monoclonal antibodies 3C6, 8A10, and 3H5 by Hawaii Biotechnology Group. The assay is based on the concentration of analyte required for 50% inhibition of antibody binding to solid phase antigen (IC₅₀).

Table 3

Sample #	Sample I.D.	Detected Taxane Concentration: µg/ml
1.	<i>Araucaria excelsa</i> (branches)	a) 1.7 b) 1.35 c) 0.9
2.	<i>Araucaria angustifolia</i> (embryo cell cultures)	a) 0.5 b) 0.75 c) ---
3.	<i>Fitzroya</i> (previous year's shoot growth)	a) 4.4 b) 3.3 c) 1.9
4.	<i>Picea abies</i> (embryogenic cell cultures)	a) 0.2 b) 0.3 c) ---
5.	<i>Picea abies</i> (embryogenic cell cultures plus colchicine)	a) 0.3 b) 0.7 c) ---
6.	<i>Cupressus</i> (embryo callus)	a) 2.5 b) 2.8 c) ---
Note: Concentration of taxanes determined by reactivity to a) anti-paclitaxel monoclonal antibody - 3C6 b) anti-taxane monoclonal antibody - 8A10 c) anti-baccatin monoclonal antibody - 3H5 Quantities listed are for the final extract solution µg/ml		

Table 4

Tissue Concentrations of Taxanes				
Taxus Sample # Production	Sample I.D.	Antibody	µg/KgFW	% of
1.	<i>Araucaria angustifolia</i> (branches)	a.	62	0.062
		b.	49	0.049
		c.	33	0.033
2.	<i>Araucaria angustifolia</i> (embryo cell cultures)	a.	10	0.010
		b.	15	0.015
		c.	--	----
3.	<i>Fitzroya</i> (previous year's shoot growth)	a.	88	0.088
		b.	66	0.066
		c.	38	0.038
4.	<i>Picea abies</i> (embryogenic cell cultures)	a.	10	0.010
		b.	15	0.015
		c.	--	----
5.	<i>Picea abies</i> (embryogenic cell cultures plus colchicine)	a.	8	0.008
		b.	20	0.020
		c.	--	----
6.	<i>Cupressus</i> (embryo callus)	a.	74	0.074
		b.	82	0.082
		c.	--	----
Note: µg/Kg-FW: micrograms per kilogram of tissue fresh weight or biomass. Reference: Taxus produces approximately 100 mg/Kg-FW, about 1000x more than the highest producer in this list. Results show that other trees have the capacity to produce taxanes that are different from paclitaxel.				

[0036] HPLC was carried out as described in Durzan and Ventimiglia, *supra*. Briefly, samples were first extracted three times in 100% methanol. A concentrated methanolic extract was mixed with 2 volumes of water and partitioned against methylene chloride twice. The methylene chloride extract was evaporated to dryness. The resulting residue was dissolved in a known volume of 100% methanol and subsequently diluted to 66% with water. This preparation was thoroughly mixed and passed through a 0.22 μm nylon filter before HPLC.

[0037] HPLC analysis was performed on 4.3 mm Taxil column (Meta-Chem Technologies, Redondo Beach, CA). A 66% methanol isocratic elution with a flow rate of 0.6 ml/min and column temperature of 25°C was used. Taxane detection (230 nm) and analysis were performed with a Hewlett Packard 1040A diode array spectrophotometer. The results of this analysis indicated the presence of taxanes in all the tissues identified in Table 2.

[0038] The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims.

Claims

1. A method of producing taxanes, the method comprising contacting plant tissue from a member of the order Con-

iferales with a composition which extracts taxanes, wherein the plant tissue is not from *Taxus spp.*

2. The method of claim 1, wherein the composition which extracts taxanes is an organic solvent.
- 5 3. The method of claim 1, wherein the composition which extracts taxanes is methanol.
4. The method of claim 1, 2 or 3, wherein the plant tissue is bark, stem, or needle tissue.
5. The method of claim 1, 2 or 3, wherein the plant tissue is from a tissue culture.
- 10 6. The method of claim 1, 2 or 3, wherein the plant tissue is from *Picea*.
7. The method of claim 1, 2 or 3, wherein the plant tissue is from *Fitzroya*.
- 15 8. The method of claim 1, 2 or 3, wherein the plant tissue is from *Cupressus*.
9. The method of any one of the preceding claims, wherein the step of recovering the taxanes includes releasing bound taxanes.
- 20 10. The method of claim 9, wherein the bound taxanes are released by treating the tissue with a glycosidase.
11. The method of claim 10, wherein the glycosidase is xylanase.
- 25 12. A method of screening plant tissue for the presence of taxanes, the method comprising
 - contacting plant tissue or an extract of the plant tissue with an antibody that is specifically reactive with taxane;
 - and
 - detecting the formation of an antigen-antibody complex;
- 30 wherein the plant tissue is from a member of the order Coniferales other than *Taxus spp.*
13. The method of claim 12, wherein the antibody is a monoclonal antibody.
14. The method of claim 12, 13 or 14, wherein the antibody is a polyclonal antiserum.
- 35 15. The method of claim 12, 13 or 14, wherein the extract of the tissue is a methanolic extract.
16. The method of claim 12 wherein the step of detecting antigen-antibody complex includes determination by competitive inhibition of an enzyme linked immunoassay.
- 40

Patentansprüche

- 45 1. Ein Verfahren zur Herstellung von Taxanen, wobei das Verfahren das Inkontaktbringen von Pflanzengewebe aus einem Mitglied der Coniferales-Ordnung mit einer Zusammensetzung umfasst, die Taxane extrahiert, worin das Pflanzengewebe nicht vom *Taxus spp.* stammt.
2. Das Verfahren gemäß Anspruch 1, worin die Zusammensetzung, die Taxane extrahiert, ein organisches Lösungsmittel ist.
- 50 3. Das Verfahren gemäß Anspruch 1, worin die Zusammensetzung, die Taxane extrahiert, Methanol ist.
4. Das Verfahren gemäß Anspruch 1, 2 oder 3, worin das Pflanzengewebe Rinden-, Stiel- oder Nadelgewebe ist.
- 55 5. Das Verfahren gemäß Anspruch 1, 2 oder 3, worin das Pflanzengewebe aus einer Gewebekultur ist.
6. Das Verfahren gemäß Anspruch 1, 2 oder 3, worin das Pflanzengewebe aus *Picea* ist.

7. Das Verfahren gemäß Anspruch 1, 2 oder 3, worin das Pflanzengewebe aus *Fitzroya* ist.
8. Das Verfahren gemäß Anspruch 1, 2 oder 3, worin das Pflanzengewebe aus *Cupressus* ist.
- 5 9. Das Verfahren gemäß einem der vorhergehenden Ansprüche, worin der Schritt der Rückgewinnung der Taxane die Freisetzung gebundener Taxane beinhaltet.
- 10 10. Das Verfahren gemäß Anspruch 9, worin die gebundenen Taxane durch Behandlung des Gewebes mit einer Glycosidase freigesetzt werden.
11. Das Verfahren gemäß Anspruch 10, worin die Glycosidase Xylanase ist.
12. Ein Verfahren zum Screenen von Pflanzengewebe nach der Anwesenheit von Taxanen, wobei das Verfahren umfasst
15 Inkontaktbringen von Pflanzengewebe oder einem Extrakt des Pflanzengewebes mit einem Antikörper, der spezifisch mit Taxan reaktiv ist; und
Detektieren der Bildung eines Antigen-Antikörper-Komplexes;
20 worin das Pflanzengewebe aus einem Mitglied der Coniferales-Ordnung ist, außer von *Taxus spp.*
13. Das Verfahren gemäß Anspruch 12, worin der Antikörper ein monoklonaler Antikörper ist.
14. Das Verfahren gemäß Anspruch 12, 13 oder 14, worin der Antikörper ein polyklonales Antiserum ist.
- 25 15. Das Verfahren gemäß Anspruch 12, 13 oder 14, worin der Extrakt des Gewebes ein methanolischer Extrakt ist.
16. Das Verfahren gemäß Anspruch 12, worin der Schritt der Detektion des Antigen-Antikörper-Komplexes die Bestimmung mittels kompetitiver Inhibierung eines Enzym-gekoppelten Immunoassays beinhaltet.
- 30

Revendications

- 35 1. Procédé de production de taxanes, ledit procédé comprenant le fait de mettre un tissu végétal provenant d'un membre de l'ordre des Coniférales en contact avec une composition permettant d'extraire les taxanes, le tissu végétal ne provenant pas de *Taxus spp.*
2. Procédé selon la revendication 1, dans lequel la composition qui sert à extraire les taxanes est un solvant organique.
- 40 3. Procédé selon la revendication 1, dans lequel la composition qui sert à extraire les taxanes est du méthanol.
4. Procédé selon l'une quelconque des revendications 1, 2 ou 3, dans lequel le tissu végétal est un tissu d'écorce, de tige ou d'aiguille.
- 45 5. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel le tissu végétal provient d'une culture de tissu.
6. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel le tissu végétal provient de *Picea*.
- 50 7. Procédé selon l'une quelconque des revendications 1 à 3 dans lequel le tissu végétal provient de *Fitzroya*.
8. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel le tissu végétal provient de *Cupressus*.
- 55 9. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel l'étape de récupération des taxanes comporte la libération des taxanes liés.
10. Procédé selon la revendication 9, dans lequel les taxanes liés sont libérés par traitement du tissu par une glyco-

sidase.

11. Procédé selon la revendication 10, dans lequel la glycosidase est une xylanase.

5 12. Procédé de recherche de présence de taxanes dans un tissu végétal, ledit procédé comprenant :

- le fait de mettre un tissu végétal ou un extrait de tissu végétal en contact avec un anticorps qui réagit spécifiquement avec un taxane et

10 le fait de détecter la formation d'un complexe antigène-anticorps dans lequel procédé le tissu végétal provient d'un membre de l'ordre des Coniférales autre que *Taxus spp.*

13. Procédé selon la revendication 12, dans lequel l'anticorps est un anticorps monoclonal.

15 14. Procédé selon l'une des revendications 12 à 14 dans lequel l'anticorps est un antisérum polyclonal.

15. Procédé selon l'une quelconque des revendications 12, 13 ou 14, dans lequel l'extrait de tissu est un extrait méthanolique.

20 16. Procédé selon la revendication 12, dans lequel l'étape de détection d'un complexe antigène-anticorps comporte une détermination par un dosage immunoenzymatique par inhibition compétitive (CIEIA).

25

30

35

40

45

50

55